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A “classical” view of  
lymphatic vasculature
The lymphatic vasculature serves as a 
one-way drainage system for extracellular 
fluid and immune cells from the periph-
ery of the body into the bloodstream. In 
general, the lymphatic vascular network 
is composed of capillaries and collecting 
vessels. Extracellular fluid and immune 
cells enter lymphatic vessels through 
permeable capillaries. Lymph then flows 
into collecting vessels through lymph 
nodes and into venous circulation. Lym-
phatic capillary permeability is achieved 
through discontinuous cell-cell junction 
organized as flap valves between lym-
phatic endothelial cells (LECs) that open 
in response to increases in extracellular 
pressure, whereas collecting vessels have 
continuous closed cell-cell junctions. 
Intraluminal valves and contractions of 
smooth muscle cells in collecting lym-
phatic vessels ensure unidirectional pro-
pulsion of lymph (1).
The transcription factor PROX1 is 
an early marker of LEC identity, and 
PROX1-induced transdifferentiation of 
blood endothelial cells (ECs) into LECs is 
a major step of lymphatic vascular develop-
ment. Signaling via receptor tyrosine kinase 
VEGFR3 expressed by LEC and VEGFR3 
ligand VEGFC produced by surrounding 
mesenchymal cells promotes lymphatic 
vessel expansion by inducing LEC pro-
liferation and migration. Developmental 
lymphangiogenesis is completed by the ear-
ly postnatal period in most tissues whereby 
lymphatic vessels mature and specialize 
to capillaries and collecting vessels and 
become VEGFC independent (1).
Schlemm’s canal: a hybrid vessel 
important for aqueous outflow
The description above is the classical view 
of adult lymphatic vasculature and is typ-
ical of what is observed in the normal skin. 
However, new genetic mouse models, 
lineage-tracing approaches, and advances 
in tissue clearing and high-resolution 
microscopy have made possible studies of 
organ-specific lymphatic vascular beds, 
including vessels in the small intestine, 
brain meninges, heart, and lymph node 
(2–5). The emerging picture is that there is 
a great deal of diversity in vessel develop-
ment, patterning, and associated molecular 
mechanisms; therefore, understanding how 
such diversity is generated by the specific 
organ and/or tissue environment and the 
significance of these differences for mainte-
nance of normal organ function is one of the 
current key challenges of vascular biology.
A case in point is Schlemm’s canal 
(SC), with recent exciting discoveries hav-
ing led to the identification of mechanisms 
controlling development and function of 
this specialized vessel. SC encircles the 
cornea and is posteriorly covered by the 
trabecular meshwork (TM), an intricate 
array of extracellular matrix fibers and 
highly specialized fibroblast-like cells of 
neural crest origin (Figure 1 and refs. 6, 7). 
SC, together with the TM, plays a key role 
in the regulation of aqueous humor out-
flow (AHO) in the eye and, consequently, 
in the regulation of intraocular pressure 
(IOP). Normally, ciliary body epithelial cell 
AH production is balanced by AH drainage 
through the TM and SC into aqueous veins 
and episcleral blood vessels (Figure 1). In 
primary open-angle glaucoma (POAG) 
— the most common type of glaucoma in 
the world — trabecular outflow draining is 
impaired, resulting in resistance to AHO 
and chronically elevated IOP, which, with 
time, irreversibly damages optic nerve 
axons (8). Importantly, reduction in IOP 
delays or prevents optic nerve damage in 
POAG and therefore represents a major 
target for therapeutic interventions (8).
SC was first described by the 19th cen-
tury German anatomist Friedrich Schlemm 
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Glaucoma is a leading cause of blindness, with an estimated world-wide 
prevalence of 3.5% in members of the population older than 40 years of 
age. Elevated intraocular pressure as the result of abnormal resistance to 
aqueous humor drainage is a major contributing, and the only preventable, 
factor in glaucoma development. Schlemm’s canal (SC), a lymphatic-like 
vessel encircling the anterior portion of the eye, plays a key role in promoting 
aqueous humor outflow and maintenance of normal intraocular pressure. 
The risk of developing glaucoma increases with age; therefore, understanding 
mechanisms of SC maintenance and how aging affects SC function are of 
special importance, both for prevention and novel treatment approaches to 
glaucoma. Using a compelling array of genetic models, Kim et al. report in 
this issue of the JCI that continuous angiopoietin/TIE2 signaling is required 
for maintaining SC identity and integrity during adulthood and show that its 
age-related changes can be rescued by a TIE2 agonistic antibody.
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tinct. During thoracic duct formation, ECs 
acquire lymphatic identity and expression 
of PROX1 before budding from embryonic 
veins, whereas in SC development, ECs first 
form the primordial blood vessel and then, 
only after this is complete, is expression of 
lymphatic markers PROX1 and VEGFR3 
initiated (10, 12, 13). In line with these find-
ings, ablation of VEGFC/VEGFR3 signaling 
completely prevents embryonic lymphatic 
vasculature development (1); however, SC 
is still formed in mice lacking both Vegfc and 
Vegfd and in Vegfr3-knockout mice, but is not 
able to grow and expand (12).
Angiopoietin/TIE pathway 
in SC development and 
maintenance
The specialized nature of the SC endothe-
lium was further brought to light after the 
identification of a key role for the angio-
poietin/TIE (ANGPT/TIE) pathway in SC 
development (11) and, as shown in this 
issue by Kim et al., in SC maintenance (15). 
Signaling of ANGPT growth factors via TIE 
receptors is important for regulating vascu-
lar stability and remodeling during devel-
opment and in numerous pathological situ-
ations in both blood and lymphatic vessels 
(16). In blood vessels, ANGPT1 acts as a 
TIE2 agonist and stabilizing factor, where-
as ANGPT2 can act both as a context- 
dependent TIE2 antagonist and a relatively 
weak agonist (16). Rescue of lymphatic 
vascular remodeling defects in Angpt2- 
deficient mice by knockin of Angpt1 indi-
cates that, unlike in blood vessels, in lym-
phatic vasculature, ANGPT2 has a primar-
ily agonistic function (17). Intriguingly, 
SC demonstrates a unique dependence 
on agonistic ANGPT/TIE2 signaling for 
its development, as mice with either dou-
ble inactivation of Angpt1 and Angpt2 or 
with Tie2 deletion completely lack SC and 
develop glaucoma (11). The importance 
of TIE2 signaling in SC development was 
further underscored by the discovery 
in 2016 of TIE2 heterozygous loss-of- 
function mutations in patients with pri-
mary congenital glaucoma (PCG) (18). 
The work from Kim et al. (15) now provides 
further fascinating insights into the mech-
anisms of SC maintenance. Through the 
detailed analysis of mice with inducible 
inactivation of Angpt1, Angpt2, and Tie2, 
Kim and colleagues show that ANGPT1 
and ANGPT2 are produced in distinct 
phenotype, characterized by expression 
of some LEC markers, such as PROX1, 
VEGFR3, integrin α9, and CCL21, as well 
as blood endothelial markers, including 
TIE2, endomucin, CD34, and plasmalem-
ma vesicle–associated protein (PLVAP) 
(10–14). Uniquely, SC ECs do not express 
two typical LEC markers, podoplanin and 
LYVE-1, that are widely used to identify 
peripheral lymphatic vessels.
Development of SC by EC sprouting 
from vein and further coalescence into a pri-
mordial vessel is reminiscent of formation of 
major embryonic lymphatic vessels, such as 
the thoracic duct (2, 10, 12). However, molec-
ularly, the two processes appear to be dis-
and was considered to be a blood vessel for 
a long time (6). However, some functional 
characteristics, such as the absence of peri-
cyte coverage, a discontinuous basement 
membrane, an absence of blood filling, and 
the known role of SC in AH and immune 
cell draining from the eye to the blood cir-
culation, led to suggestions that SC shares 
traits with the lymphatic vasculature (9). 
This mystery was solved definitively in 
2014, when several research teams inde-
pendently described the developmental 
origins and molecular mechanisms of 
SC formation (10–14). SC was shown to 
develop postnatally from the choroidal 
vein and to present a hybrid molecular 
Figure 1. Role of the ANGPT/TIE2 pathway in maintenance of SC. Aqueous humor (AH) produced 
by ciliary body epithelium is drained primarily via TM and SC situated at the iridocorneal angle of the 
eye. Equilibrium between AH production and drainage is essential for maintenance of normal IOP. 
Under normal conditions in which Tie2 can actively signal, ECs of the inner wall of SC, juxtaposed to 
TM, are subjected to the gradients of pressure and AH flow. They are characterized by high expression 
of PROX1, TIE2, VEGFR3, and KLF4 and the presence of giant vacuoles, pressure-dependent EC out-
pouches that provide a passageway for AH flow across SC wall. SC mural cells and the TM are sources 
of ANGPT1 and -2, respectively. ANGPT/TIE2 signaling maintains SC integrity and function; its inac-
tivation leads to loss of SC EC specialization, including decreased expression of PROX1, VEGFR3, and 
KLF4, and ultimately results in SC degeneration and increased IOP.
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